All In Biotech

Free tool

FAERS Monitor: Lotrimin Ultra

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 19, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 021307 or its brand name (Lotrimin Ultra, Butenafine Hydrochloride). Reports on generic versions are filed under their own applications.

Reports

578

Serious

61

11% of reports

Hospitalization

24

Death reported

7

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • drug ineffective185
  • off label use59
  • product use issue43
  • product use in unapproved indication34
  • pruritus33
  • condition aggravated29
  • rash21
  • drug ineffective for unapproved indication20
  • drug effective for unapproved indication19
  • erythema19
  • drug effect decreased18
  • product administered at inappropriate site15
  • burning sensation12
  • pain12
  • product prescribing issue12

Reports by year received

View as table
YearReports
20041
20052
20062
20071
20081
20101
20111
201241
201381
201461
201525
201631
201741
201842
201932
202028
202124
202227
202338
202430
202539
202629

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,581 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
product administered at inappropriate siteSignal1529.818.1389
drug effective for unapproved indicationSignal1923.615.2390
product prescribing issueSignal1220.111.5199
drug ineffective for unapproved indicationSignal2013.38.6215
drug effect decreasedSignal1812.27.7174
product use issueSignal438.36.2272
burning sensationSignal126.23.648
drug ineffectiveSignal1855.14.5648
product use in unapproved indicationSignal345.03.6106
condition aggravatedSignal293.52.449
erythemaSignal193.42.230
pruritusSignal333.12.246
off label useSignal592.51.951
rash211.81.26
pain120.70.41

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.